Treatable Ataxias: How to Find the Needle in the Haystack?
Open Access
- 7 September 2022
- journal article
- review article
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 15 (3) , 206-226
Abstract
Treatable ataxias are a group of ataxic disorders with specific treatments. These disorders include genetic and metabolic disorders, immune-mediated ataxic disorders, and ataxic disorders associated with infectious and parainfectious etiology, vascular causes, toxins and chemicals, and endocrinopathies. This review provides a comprehensive overview of different treatable ataxias. The major metabolic and genetic treatable ataxic disorders include ataxia with vitamin E deficiency, abetalipoproteinemia, cerebrotendinous xanthomatosis, Niemann-Pick disease type C, autosomal recessive cerebellar ataxia due to coenzyme Q10 deficiency, glucose transporter type 1 deficiency, and episodic ataxia type 2. The treatment of these disorders includes the replacement of deficient cofactors and vitamins, dietary modifications, and other specific treatments. Treatable ataxias with immune-mediated etiologies include gluten ataxia, anti-glutamic acid decarboxylase antibody-associated ataxia, steroid-responsive encephalopathy associated with autoimmune thyroiditis, Miller-Fisher syndrome, multiple sclerosis, and paraneoplastic cerebellar degeneration. Although dietary modification with a gluten-free diet is adequate in gluten ataxia, other autoimmune ataxias are managed by short-course steroids, plasma exchange, or immunomodulation. For autoimmune ataxias secondary to malignancy, treatment of tumor can reduce ataxic symptoms. Chronic alcohol consumption, antiepileptics, anticancer drugs, exposure to insecticides, heavy metals, and recreational drugs are potentially avoidable and treatable causes of ataxia. Infective and parainfectious causes of cerebellar ataxias include acute cerebellitis, postinfectious ataxia, Whipple’s disease, meningoencephalitis, and progressive multifocal leukoencephalopathy. These disorders are treated with steroids and antibiotics. Recognizing treatable disorders is of paramount importance when dealing with ataxias given that early treatment can prevent permanent neurological sequelae.Keywords
This publication has 174 references indexed in Scilit:
- Heterogeneity of Coenzyme Q10DeficiencyArchives of Neurology, 2012
- The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patientsMolecular Genetics and Metabolism, 2012
- The effectiveness of long-term dietary therapy in the treatment of adult Refsum diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Niemann-Pick disease type COrphanet Journal of Rare Diseases, 2010
- Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisThe Lancet Neurology, 2010
- Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical managementneurogenetics, 2009
- Abetalipoproteinemia: two case reports and literature reviewOrphanet Journal of Rare Diseases, 2008
- Hashimoto's encephalopathy presenting with progressive cerebellar ataxiaJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPAgene in Italian familiesNeurological Sciences, 2004
- Multiple sclerosis in childhood: Clinical profile in 125 patientsThe Journal of Pediatrics, 1987